Novartis’s Biosimilar Rituxan Is ‘On Track,’ Sandoz Head Says

Novartis AG’s development of a version of the best-selling drug Rituxan is proceeding as planned, Jeff George, who heads the company’s Sandoz generics unit, said in an interview today.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.